Partial
bladder outlet obstruction (PBOO), a common urologic pathology mostly caused by
benign prostatic hyperplasia, can coexist in 40-45% of patients with
overactive bladder (OAB) and is associated with detrusor overactivity (DO). PBOO that induces DO results in alteration in bladder
myosin II type and
isoform composition.
Blebbistatin (
BLEB) is a
myosin II inhibitor we recently demonstrated potently relaxed normal detrusor smooth muscle (SM) and reports suggest varied
BLEB efficacy for different SM
myosin (SMM)
isoforms and/or SMM vs nonmuscle
myosin (NMM). We hypothesize
BLEB inhibition of
myosin II as a novel contraction
protein targeted strategy to regulate DO. Using a surgically-induced male rat PBOO model, organ bath contractility, competitive and Real-Time-RT-PCR were performed. It was found that obstructed-bladder weight significantly increased 2.74-fold while in vitro contractility of detrusor to various stimuli was impaired ∼50% along with decreased shortening velocity. Obstruction also altered detrusor spontaneous activities with significantly increased amplitude but depressed frequency. PBOO switched bladder from a phasic-type to a more tonic-type SM. Expression of 5'
myosin heavy chain (MHC) alternatively spliced
isoform SM-A (associated with tonic-type SM) increased 3-fold while 3' MHC SM1 and essential light chain
isoform MLC(17b) also exhibited increased relative expression. Total SMMHC expression was decreased by 25% while the expression of NMM IIB (SMemb) was greatly increased by 4.5-fold.
BLEB was found to completely relax detrusor strips from both
sham-operated and PBOO rats pre-contracted with KCl,
carbachol or electrical field stimulation although sensitivity was slightly decreased (20%) only at lower doses for PBOO. Thus we provide the first thorough characterization of the response of rat bladder
myosin to PBOO and demonstrate complete
BLEB-induced PBOO bladder SM relaxation. Furthermore, the present study provides valuable evidence that
BLEB may be a novel type of potential therapeutic agent for regulation of myogenic and nerve-evoked DO in OAB.